Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 751 to 765 of 1112 results for criteria

  1. Alemtuzumab for treating highly active relapsing–remitting multiple sclerosis (TA312)

    Evidence-based recommendations on alemtuzumab (Lemtrada) for treating highly active relapsing–remitting multiple sclerosis in adults.

    Technology appraisal guidance
    Last updated
    21 May 2024
    View recommendations

    Sections for TA312

  2. Multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis (HTG441)

    Evidence-based recommendations on multiple frequency bioimpedance devices to guide fluid management in people with chronic kidney disease having dialysis.

    HealthTech guidance
    Published
    21 June 2017
    View recommendations

    Sections for HTG441

  3. Nintedanib for treating idiopathic pulmonary fibrosis when forced vital capacity is above 80% predicted (TA864)

    Evidence-based recommendations on nintedanib (Ofev) for treating idiopathic pulmonary fibrosis in adults when forced vital capacity is above 80% predicted.

    Technology appraisal guidance
    Published
    1 February 2023
    View recommendations

    Sections for TA864

  4. Clopidogrel and modified-release dipyridamole for the prevention of occlusive vascular events (TA210)

    Evidence-based recommendations on clopidogrel and modified-release dipyridamole for preventing occlusive vascular events in adults.

    Technology appraisal guidance
    Published
    15 December 2010
    View recommendations

    Sections for TA210

  5. BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume (MIB50)

    NICE has developed a medtech innovation briefing (MIB) on the BladderScan BVI 9400 3D portable ultrasound scanner for measuring bladder volume

    Medtech innovation briefing
    Published
    22 January 2016

  6. Leadless cardiac pacemaker implantation for bradyarrhythmias (IPG626)

    Evidence-based recommendations on leadless cardiac pacemaker implantation for bradyarrhythmias in adults. This involves inserting a device into the heart that helps it beat at a normal rate.

    Interventional procedures guidance
    Published
    29 August 2018
    View recommendations

    Sections for IPG626

  7. The evidence on the safety of reinforcement of a permanent stoma with a synthetic or biological mesh to prevent a parastomal hernia shows there are serious but well-recognised complications. The evidence on efficacy is limited in quantity and quality. Therefore, this procedure should not be used unless  special arrangements   are in place for clinical governance, consent, and audit or research.

    of all patients having the procedure. NICE has identified relevant audit criteria and has developed an audit tool (which is for use at...

    Research recommendation
    Published
    15 November 2019

  8. Narrow band imaging for Barrett's oesophagus (MIB179)

    NICE has developed a medtech innovation briefing (MIB) on narrow band imaging for Barrett’s oesophagus .

    Medtech innovation briefing
    Published
    29 March 2019

  9. Digitally enabled therapies for adults with anxiety disorders: early value assessment (HTE9)

    Early value assessment (EVA) guidance on digitally enabled therapies for adults with anxiety disorders....

    Health technology evaluation
    Last updated
    14 December 2023
    View recommendations

    Sections for HTE9

  10. Digital technologies for assessing attention deficit hyperactivity disorder (ADHD) (HTG729)

    Evidence-based recommendations on digital technologies for assessing attention deficit hyperactivity disorder (ADHD).

    HealthTech guidance
    Published
    21 October 2024
    View recommendations

    Sections for HTG729

  11. Linzagolix for treating moderate to severe symptoms of uterine fibroids (TA996)

    Evidence-based recommendations on linzagolix (Yselty) for treating moderate to severe symptoms of fibroids in adults of reproductive age.

    Technology appraisal guidance
    Published
    14 August 2024
    View recommendations

    Sections for TA996

  12. Etranacogene dezaparvovec for treating moderately severe or severe haemophilia B (TA989)

    Evidence-based recommendations on etranacogene dezaparvovec (Hemgenix) for treating moderately severe or severe haemophilia B in adults.

    Technology appraisal guidance
    Published
    24 July 2024

    Sections for TA989

  13. Obinutuzumab for untreated advanced follicular lymphoma (TA513)

    Evidence-based recommendations on obinutuzumab (Gazyvaro) for untreated advanced follicular lymphoma in adults.

    Technology appraisal guidance
    Published
    21 March 2018
    View recommendations

    Sections for TA513

  14. Enzalutamide for treating hormone-sensitive metastatic prostate cancer (TA712)

    Evidence-based recommendations on enzalutamide (Xtandi) for treating hormone-sensitive metastatic prostate cancer in adults.

    Technology appraisal guidance
    Published
    7 July 2021
    View recommendations

    Sections for TA712

  15. Teclistamab for treating relapsed and refractory multiple myeloma after 3 or more treatments (TA1015)

    Evidence-based recommendations on teclistamab (Tecvayli) for relapsed and refractory multiple myeloma after 3 or more treatments in adults.

    Technology appraisal guidance
    Published
    13 November 2024
    View recommendations

    Sections for TA1015